Aunt Minnie (6/6) reports that according to a study published online May 28 in Clinical Radiology, “breast MRI improves the positive predictive value (PPV) of BI-RADS category 4B (moderate suspicion of malignancy) for mammographic microcalcifications.” Researchers concluded, “If amorphous microcalcification with regional or grouped distribution on mammography shows no enhancement on MRI, follow-up could be considered rather than immediate biopsy,” adding, “In addition, breast MRI might have the potential to guide the best site to biopsy in category 4B microcalcification.”
Aunt Minnie (6/5) reports Vermont Gov. Phil Scott (R) signed HB 639 into law, which “requires insurers in that state to cover additional breast imaging services without enforcing cost-sharing requirements.” The state’s Department of Financial Regulation “will release a regulatory guidance outlining the coding structure for screening mammograms, ultrasound scans, and callback screenings.”
Aunt Minnie (6/5, Yee) reports researchers found that “the combination of digital mammography (DM) plus digital breast tomosynthesis (DBT) finds 90% more breast cancer than digital mammography alone – and with a similar recall rate.” The findings were published in the journal Radiology. HemOnc Today (6/5, Polhamus) also covers the story.
HealthDay (6/5, Dallas) reports researchers found “older women who get mammograms are more likely to also seek screenings for cervical cancer and osteoporosis.” The findings were published in the journal Radiology.
Aunt Minnie (6/5, Yee) and the Radiology Business Journal (6/5, Walter) also cover the story.
The New York Times (6/3, Grady, Subscription Publication) reports that research indicates “many women with early-stage breast cancer who would receive chemotherapy under current standards do not actually need it, according to a major international study that is expected to quickly change medical treatment.” Investigators “found that gene tests on tumor samples were able to identify women who coustyle="color:#0E4DA4"ld safely skip chemotherapy and take only a drug that blocks the hormone estrogen or stops the body from making it.” The findings were published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology meeting.